Compare Abeona Therapeutics Inc (ABEO) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Western Alliance Bancorporation trades at $78.78 (market cap $9.01B). The key difference: Western Alliance Bancorporation is far larger — about 24.1× Abeona Therapeutics Inc's market cap, and Western Alliance Bancorporation pays a 2.04% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WAL | |
|---|---|---|
Market Cap | $373.32M | $9.01B |
Sector | Health | Financials |
52-Week High | $7.23 | $96.08 |
52-Week Low | $4.17 | $66.70 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Western Alliance Bancorporation (WAL) trades at $82.50, up 1.18% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 9.6 and net income margin of 25.63%. Recent news highlights business expansion and industry recognition, including a #1 ranking in Arizona by Forbes.
The outlook is positive, driven by earnings momentum and a consensus price target of $90.67, offering ~10% upside. Risks include negative operating cash flow and high interest expenses, but strong institutional buy ratings and recent corporate developments support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
